{"id":"NCT01318733","sponsor":"Galderma R&D","briefTitle":"Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","officialTitle":"A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-06","completion":"2012-07","firstPosted":"2011-03-18","resultsPosted":"2014-01-08","lastUpdate":"2021-02-18"},"enrollment":449,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"CD07805/47 gel 0.5%","otherNames":[]}],"arms":[{"label":"CD07805/47 Gel 0.5%","type":"EXPERIMENTAL"}],"summary":"A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.","primaryOutcome":{"measure":"Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea.","timeFrame":"Over 1 year","effectByArm":[{"arm":"CD07805/47 Gel 0.5% QD","deltaMin":-1.5,"sd":0.88}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":449},"commonTop":["Flushing","Erythema","Rosacea"]}}